Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.
All communications on the use of transdermal fentanyl as well as the recommendations of the manufacturer include the direction that patients should be titrated with a short-acting narcotic to control their cancer pain before they are converted to a fentanyl transdermal therapeutic system (TTS). We investigated the possibility of avoiding this titration phase by immediate fentanyl TTS therapy in patients with uncontrolled cancer pain. Dose finding was performed by direct titration of fentanyl TTS according to clinical necessity on a day-to-day basis. Morphine solution for rescue medication was available. Short-term follow-up was 28 days, and 20 patients (10 in- and 10 outpatients) were evaluable. On the average, sufficient pain control [visual analogue scale (VAS) < 35 mm] was reached within 48 h of the start of fentanyl TTS. The mean VAS values before and during fentanyl TTS therapy were 53 mm (before), 27 mm (week 1), 21 mm (week 2), 18 mm (week 3) and 21 mm (week 4). There were statistically significant lower VAS values at all follow-up times compared to pretreatment values (e.g. pretreatment to day 1: P = 0.019; pretreatment to day 28: P = 0.002; Wilcoxon sign-rank test). The mean fentanyl TTS doses were 70 micrograms/h (week 1), 98 micrograms/h (week 2), 107 micrograms/h (week 3) and 116 micrograms/h (week 4). The differences of mean fentanyl TTS does were significantly different between days 1 and 7 (P < 0.001) and between days 8 and 14 (P = 0.006), but not between days 15 and 21 and days 22 and 28.(ABSTRACT TRUNCATED AT 250 WORDS)
Korte
W
W
IKCH, Division of Hematology, Kantonsspital, St. Gallen, Switzerland.
Morant
R
R
D000279:Administration, Cutaneous; D000284:Administration, Oral; D005283:Fentanyl / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000503:physiopathology*; D010146:Pain / Q000188:drug therapy / Q000517:prevention & control*; D010147:Pain Measurement; D010865:Pilot Projects; D011446:Prospective Studies; D012119:Respiration / Q000187:drug effects; D013997:Time Factors; D017186:Titrimetry
D009020:Morphine; D005283:Fentanyl